

Evaluating the Safety of Shortened Infusion Times for different Oncological Immunotherapie

NCT06031233

Status	RECRUITING
Phase	Phase 4
Sponsor	Isala
Enrollment	776 participants

Key Eligibility Criteria

Inclusion (4)

- Starting treatment with monoclonal antibodies: nivolumab, pembrolizumab ipilimumab, bevacizumab, trastuzumab, durvalumab or atezolizumab.
- years and older.
- No known history of increased susceptibility to immunological reactions.
- Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.

Exclusion (4)

- Other research medication within 4 weeks of the start of the study.
- Inclusion in medical research in which the administration of medication should follow its stated times and dosages of infusions
- Dosage deviates from standard protocol
- Patients whom receive drugs through a central venous catheter (and for example porth-a-cath).

Locations (1 total)

Isala Hospital, Zwolle, Netherlands